New York, New York The Cancer Research Institute (CRI) announced today that it has brought together the Cancer Vaccine Consortium, a program of the Sabin Vaccine Institute, and the Cancer Vaccine Collaborative, a program of the Cancer Research Institute (CRI) and the Ludwig Institute for Cancer Research (LICR), to form the leading initiative on cancer vaccines. This joint effort establishes a unified voice in the cancer vaccine field and provides a major new resource to academia, industry, and governmental agencies involved in cancer vaccine discovery and development.
The Cancer Vaccine Consortium, now administered by the Cancer Research Institute, is an international association of 67 pharmaceutical, biotechnology, and academic institutions engaged in cancer vaccine and immunotherapy research and development. The Cancer Vaccine Collaborative is a coordinated global network of 22 academic clinical and laboratory centers with strong immune monitoring capabilities and the capacity to conduct early-phase clinical trials.
Linking these programs under a single organization offers great synergism for academic and industrial collaboration and provides improved capabilities for all its members. Together, the two programs aim to address the needs of the immunotherapy community with the goal to accelerate discovery and development, and facilitate regulatory discussions about cancer vaccines and other immunotherapies.
The objectives and activities of the new Cancer Vaccine Consortium will encompass:
Lloyd J. Old, M.D., chairman of the Ludwig Institute for Cancer Research, director of the Cancer Research Institute Scientific Advisory Council, and director of the CRI/LICR Cancer Vaccine Collaborative, will also serve as director of the CRI Cancer Vaccine Consortium and chairman of its Executive Committee. Axel Hoos, M.D., Ph.D., medical lead in Immuno-Oncology at Bristol-Myers Squibb Company and former president of the Sabin Vaccine Institutes Cancer Vaccine Consortium, will serve as co-chairman of the Cancer Vaccine Consortium Executive Committee.
The time is ripe for stronger alliances between academia and industry, says Dr. Old. Integrating the clinical trials network of the CRI/LICR Cancer Vaccine Collaborative with the strengths of the pharmaceutical, biotech, and academic membership of the Sabin Cancer Vaccine Consortium will allow the Cancer Research Institute to present a single, united front on cancer vaccines to the scientific and medical communities. This alignment strengthens the overall position of all of its participants and establishes a unified voice that can represent the needs of a broader constituency.
Dr. Hoos anticipates that the joint effort will play a key role in facilitating knowledge exchange and creating a fertile environment for advances in cancer immunotherapy. The Sabin Vaccine Institutes Cancer Vaccine Consortium had very successfully begun to address issues of clinical paradigm development, immune assay harmonization, and regulatory dialogue, Dr. Hoos says. Based on the Consortiums track record of bringing stakeholders together, identifying needs, and addressing them through focused initiatives, the alliance with CRI promises growth and delivery of further concrete solutions, which can be adopted widely.
The Cancer Research Institute has fostered the fields of immunology and tumor immunology over the past 54 years through the provision of research and training grants to academic investigators, and dedicates approximately 35 percent of its annual research budget to the support of cancer vaccine research. By incorporating the Sabin Vaccine Institutes Cancer Vaccine Consortium into the Cancer Research Institutes clinical investigation efforts, we are expanding CRIs reach and ability to deliver accelerated progress in this growing field, says Jill ODonnell-Tormey, Ph.D., executive director of the Cancer Research Institute. That should be very appealing to the Institutes donors who wish to make an impact on cancer with measurable outcomes that can be realized within a short period of time, she adds.
|Contact: Brian Brewer|
Cancer Research Institute